{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:11:06Z","timestamp":1780405866132,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108030"],"award-info":[{"award-number":["82020108030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20416"],"award-info":[{"award-number":["U21A20416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118420","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T19:21:24Z","timestamp":1758828084000},"page":"118420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Research progress on anti-tumor drug resistance of pyridazine-containing structural compounds"],"prefix":"10.1016","volume":"131","author":[{"given":"Yu-Lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Po","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmc.2025.118420_bb0005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.15537\/1658-3175.8333","article-title":"Global cancer burden growing, amidst mounting need for services","volume":"45","year":"2024","journal-title":"Saudi Med J"},{"issue":"9","key":"10.1016\/j.bmc.2025.118420_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094806","article-title":"Multidrug resistance in mammals and fungi-from MDR to PDR: A rocky road from atomic structures to transport mechanisms","volume":"22","author":"Khunweeraphong","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.bmc.2025.118420_bb0015","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1039\/C1MD00074H","article-title":"Are pyridazines privileged structures?","volume":"2","author":"Wermuth","year":"2011","journal-title":"MedChemComm"},{"issue":"9","key":"10.1016\/j.bmc.2025.118420_bb0020","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00044-023-03035-9","article-title":"The pyridazine heterocycle in molecular recognition and drug discovery","volume":"32","author":"Meanwell","year":"2023","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2025.118420_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117847","article-title":"Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: an updated review","volume":"111","author":"Liu","year":"2024","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2025.118420_bb0030","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ddr.22118","article-title":"Pyridazine derivatives as selective COX-2 inhibitors: a review on recent updates","volume":"84","author":"Ewieda","year":"2023","journal-title":"Drug Develop Res"},{"issue":"8","key":"10.1016\/j.bmc.2025.118420_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200067","article-title":"Anti-inflammatory activity of pyridazinones: a review","volume":"355","author":"Hassan","year":"2022","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmc.2025.118420_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2019.127084","article-title":"Synthesis, crystal structures and biological evaluation of new pyridazine derivatives","volume":"1200","author":"Singh","year":"2020","journal-title":"J Mol Struct"},{"issue":"12","key":"10.1016\/j.bmc.2025.118420_bb0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ardp.200300775","article-title":"New antithrombotic 1-phthalazinamines with serotonin antagonistic properties","volume":"336","author":"Johnsen","year":"2003","journal-title":"Arch Pharm"},{"issue":"4","key":"10.1016\/j.bmc.2025.118420_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2023.104636","article-title":"Synthesis of novel 5-HT1A arylpiperazine ligands: binding data and computer-aided analysis of pharmacological potency","volume":"16","author":"Penji\u0161evi\u0107","year":"2023","journal-title":"Arab J Chem"},{"issue":"11","key":"10.1016\/j.bmc.2025.118420_bb0055","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1021\/acsmedchemlett.9b00430","article-title":"Discovery of a potent and selective TRPC5 inhibitor, efficacious in a focal segmental glomerulosclerosis model","volume":"10","author":"Yu","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118420_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139514","article-title":"Effective scaffolds as antihypertensive agents, a long story with happy endings; a review tracing the promising reported candidates","volume":"1319","author":"Aziz","year":"2025","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2025.118420_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111912","article-title":"Synthesis and discovery of triazolo-pyridazine-6-yl-substituted piperazines as effective anti-diabetic drugs; evaluated over dipeptidyl peptidase-4 inhibition mechanism and insulinotropic activities","volume":"187","author":"Bindu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0070","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c02846","article-title":"Brain penetrant NLRP3 inhibitors: the discovery of a panacea?","author":"Harrison","year":"2024","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118420_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2024.101830","article-title":"New thiazol-pyridazine derivatives as antimicrobial and antiviral candidates: synthesis, and application","volume":"28","author":"Alatawi","year":"2024","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.bmc.2025.118420_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115698","article-title":"Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis","volume":"168","author":"Yan","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.bmc.2025.118420_bb0085","article-title":"PARP1: a comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments","volume":"1880","author":"Concei\u00e7\u00e3o","year":"2025","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118420_bb0090","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c02129","article-title":"Rational design, synthesis, and biological evaluation of novel c-met degraders for lung cancer therapy","author":"Qiu","year":"2025","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2025.118420_bb0095","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-Met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-Met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.bmc.2025.118420_bb0100","doi-asserted-by":"crossref","first-page":"12314","DOI":"10.1021\/acs.jmedchem.4c01004","article-title":"Discovery of potent and selective c-Met degraders for hepatocellular carcinoma treatment","volume":"67","author":"Min","year":"2024","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.bmc.2025.118420_bb0105","doi-asserted-by":"crossref","first-page":"15140","DOI":"10.1021\/acs.jmedchem.2c00981","article-title":"Discovery of D6808, a highly selective and potent macrocyclic c-met inhibitor for gastric cancer harboring MET gene alteration treatment","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmc.2025.118420_bb0110","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1021\/acs.jmedchem.9b00188","article-title":"Inhibiting hedgehog: an update on pharmacological compounds and targeting strategies","volume":"62","author":"Galperin","year":"2019","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118420_bb0115","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40264-018-0777-5","article-title":"Safety and tolerability of sonic hedgehog pathway inhibitors in cancer","volume":"42","author":"Carpenter","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.bmc.2025.118420_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117051","article-title":"Design, synthesis and biological evaluation of novel 4-aminopiperidine derivatives as SMO\/ERK dual inhibitors","volume":"74","author":"Zhang","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114040","article-title":"Discovery of spiro amide SHR902275: a potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers","volume":"228","author":"Zhao","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2025.118420_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119928","article-title":"AXL kinase inhibitor exhibits antitumor activity by inducing apoptotic cell death in triple-negative breast cancer cells","volume":"2025","author":"Woo","year":"1872","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"10.1016\/j.bmc.2025.118420_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114253","article-title":"Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis","volume":"234","author":"Shi","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118420_bb0140","article-title":"Roles of CDK12 mutations in PCa development and treatment","volume":"1880","author":"Jiang","year":"2025","journal-title":"Biochim Biophys Acta (BBA) \u2013 Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118420_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155922","article-title":"The role of the androgen receptor (AR) in endometrial cancer aggressiveness: correlation with other prognostic markers and therapeutic implications. A retrospective observational study","volume":"269","author":"Paudice","year":"2025","journal-title":"Pathology \u2013 Res Pract"},{"key":"10.1016\/j.bmc.2025.118420_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116400","article-title":"Novel selective agents for the degradation of AR\/AR-V7 to treat advanced prostate cancer","volume":"271","author":"Yang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2025.118420_bb0155","doi-asserted-by":"crossref","first-page":"14466","DOI":"10.1021\/acs.jmedchem.4c01232","article-title":"Discovery of pyrazolopyrazines as selective, potent, and mutant-active MET inhibitors with intracranial efficacy","volume":"67","author":"Bumpers","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118420_bb0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acs.jmedchem.4c02642","article-title":"The potential of PARP inhibitors as antitumor drugs and the perspective of molecular design","volume":"68","author":"Wang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114417","article-title":"Rational design, synthesis and biological evaluation of dual PARP-1\/2 and TNKS1\/2 inhibitors for cancer therapy","volume":"237","author":"Xu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115709","article-title":"Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities","volume":"259","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107556","article-title":"Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors","volume":"151","author":"Wu","year":"2024","journal-title":"Bioorg Chem"},{"issue":"17","key":"10.1016\/j.bmc.2025.118420_bb0185","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.1021\/acs.jmedchem.3c00821","article-title":"YCH1899, a highly effective phthalazin-1(2H)-one derivative that overcomes resistance to prior PARP inhibitors","volume":"66","author":"Sun","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138949","article-title":"Explorations of novel MDR-related hub genes and the potential roles TRIM9 played in drug-resistant hepatocellular carcinoma","volume":"290","author":"Xiao","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bmc.2025.118420_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114231","article-title":"Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel","volume":"233","author":"Shi","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105740","article-title":"Controlled microwave-assisted reactions: a facile synthesis of polyfunctionally substituted phthalazines as dual EGFR and PI3K inhibitors in CNS SNB-75 cell line","volume":"122","author":"Hassan Nazmy","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117231","article-title":"Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK inhibitors","volume":"285","author":"Xu","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2025.118420_bb0210","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the first highly selective and broadly effective macrocycle-based type II TRK inhibitors that overcome clinically acquired resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmc.2025.118420_bb0215","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1021\/acs.jmedchem.3c00899","article-title":"Structure-based optimization of the third generation type II macrocycle TRK inhibitors with improved activity against solvent-front, xDFG, and gatekeeper mutations","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114899","article-title":"Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy","volume":"245","author":"Xiang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108189","article-title":"The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia","volume":"156","author":"Qian","year":"2025","journal-title":"Bioorg Chem"},{"issue":"16","key":"10.1016\/j.bmc.2025.118420_bb0230","doi-asserted-by":"crossref","first-page":"10898","DOI":"10.1021\/acs.jmedchem.1c01853","article-title":"Designing novel BCR-ABL inhibitors for chronic myeloid leukemia with improved cardiac safety","volume":"65","author":"Pandrala","year":"2022","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmc.2025.118420_bb0235","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR\u2013ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2025.118420_bb0240","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1021\/acs.jmedchem.1c00082","article-title":"Discovery of a candidate containing an (S)-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden scaffold as a highly potent pan-inhibitor of the BCR-ABL kinase including the T315I-resistant mutant for the treatment of chronic myeloid leukemia","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0245","article-title":"HDAC11 inhibition as a potential therapeutic strategy for AML: target identification, lead discovery, antitumor potency, and mechanism investigation","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025886","article-title":"FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells","author":"Araujo","year":"2025","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bmc.2025.118420_bb0255","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.1021\/acs.jmedchem.3c00575","article-title":"Inhibition of FLT3-ITD kinase in acute myeloid leukemia by new imidazo[1,2-b]pyridazine derivatives identified by scaffold hopping","volume":"66","author":"B\u0159ehov\u00e1","year":"2023","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2025.118420_bb0260","article-title":"The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer","volume":"6","author":"Sattler","year":"2025","journal-title":"Cell Rep Med"},{"issue":"41","key":"10.1016\/j.bmc.2025.118420_bb0265","doi-asserted-by":"crossref","first-page":"30346","DOI":"10.1039\/D4RA04036H","article-title":"Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3-b]pyridazine derivatives as dual c-met\/Pim-1 potential inhibitors with antitumor activity","volume":"14","author":"Mahmoud","year":"2024","journal-title":"RSC Adv"},{"issue":"27","key":"10.1016\/j.bmc.2025.118420_bb0270","doi-asserted-by":"crossref","first-page":"16482","DOI":"10.1021\/acsomega.0c00838","article-title":"Discovery of triazolo-pyridazine\/-pyrimidine derivatives bearing aromatic (heterocycle)-coupled azole units as class II c-Met inhibitors","volume":"5","author":"Zhang","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2025.118420_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115122","article-title":"A first-in-human phase 1\/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies","volume":"216","author":"Ribrag","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2025.118420_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112092","article-title":"Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma","volume":"190","author":"Chen","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102345","article-title":"TTC7A-ALK, a novel ALK fusion variant identified in a patient with metastatic lung adenocarcinoma, exhibits excellent response to crizotinib","volume":"54","author":"Huang","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bmc.2025.118420_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129309","article-title":"Discovery of imidazo[1,2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants","volume":"89","author":"Xiao","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118420_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108083","article-title":"Rearranged during transfection (RET) lung cancer \u2013 update on targeted therapies","volume":"200","author":"Mullally","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmc.2025.118420_bb0300","doi-asserted-by":"crossref","unstructured":"Maturi, A.; Sastry, K. N. V.; Kumar, S.; Pogaku, V.; Kwon, H. J.; Ahn, S.-M.; Kim, M.-H. Side chain investigation of imidazopyridazine as a hinge binder for targeting actionable mutations of RET kinase. ACS Med Chem Lett 2024, 15 (9), 1566\u20131574. DOI: https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00287.","DOI":"10.1021\/acsmedchemlett.4c00287"},{"key":"10.1016\/j.bmc.2025.118420_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156883","article-title":"LINC-PINT suppresses the progression of acute myeloid leukemia via miR-767-5p\/SUZ12-mediated JAK\/STAT signaling pathway","volume":"188","author":"Xiang","year":"2025","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.bmc.2025.118420_bb0310","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.chembiol.2023.05.007","article-title":"New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation","volume":"30","author":"Arwood","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2025.118420_bb0315","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bioorg.2019.03.068","article-title":"Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold","volume":"87","author":"Elmasry","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117378","article-title":"Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12\/13","volume":"288","author":"Xia","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118420_bb0325","doi-asserted-by":"crossref","unstructured":"Kharbanda, A.; Zhang, L.; Saha, D.; Tran, P.; Xu, K.; Li, M. O.; Leung, Y.-K.; Frett, B.; Li, H.-y. Discovery and biological evaluation of phthalazines as novel non-kinase TGF\u03b2 pathway inhibitors. Eur J Med Chem 2021, 223, 113660. Doi:https:\/\/doi.org\/10.1016\/j.ejmech.2021.113660.","DOI":"10.1016\/j.ejmech.2021.113660"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500361X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500361X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:33:17Z","timestamp":1780403597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962500361X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"alternative-id":["S096808962500361X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118420","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on anti-tumor drug resistance of pyridazine-containing structural compounds","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118420"}}